|
"The few, the proud, the profitable" could be Genentech's motto. One of the world's oldest and most successful biotechs (in an industry full of money-losers), the firm has a number of blockbuster cancer therapies based on its antibody (protein) technologies. Its oncology portfolio contains Rituxan (non-Hodgkin's lymphoma), Avastin (colorectal and lung cancers), Herceptin (breast cancer), Tarceva (lung cancer), Xeloda (metastatic colorectal cancer), and Zelboraf (inoperable melanoma). Other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Genentech is wholly owned by Swiss drugmaker Roche.
|
